Mehrian Jafarizade to Risk Factors
This is a "connection" page, showing publications Mehrian Jafarizade has written about Risk Factors.
Connection Strength
0.089
-
Kahe F, Sharfaei S, Pitliya A, Jafarizade M, Seifirad S, Habibi S, Chi G. Coronary artery tortuosity: a narrative review. Coron Artery Dis. 2020 03; 31(2):187-192.
Score: 0.019
-
Chi G, Gibson CM, Kalayci A, Cohen AT, Hernandez AF, Hull RD, Kahe F, Jafarizade M, Sharfaei S, Liu Y, Harrington RA, Goldhaber SZ. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 04; 45(4):477-487.
Score: 0.018
-
Chi G, Sharfaei S, Jafarizade M, Kahe F, Liu Y. Extended or shorter prophylaxis for venous thromboembolism in acutely ill hospitalized patients: Updated meta-analysis of randomized trials. Vasc Med. 2019 Apr; 24(2):156-158.
Score: 0.018
-
Nafee T, Gibson CM, Yee MK, Alkhalfan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpasand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouz M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. Expert Rev Cardiovasc Ther. 2018 Nov; 16(11):845-855.
Score: 0.017
-
Pitliya A, Datta S, Kalayci A, Kahe F, Sharfaei S, Jafarizade M, Goudarzi S, Chi G. Eosinophilic inflammation in spontaneous coronary artery dissection: A potential therapeutic target? Med Hypotheses. 2018 Dec; 121:91-94.
Score: 0.017